Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karyopharm Therapeutics Inc.

www.karyopharm.com

Latest From Karyopharm Therapeutics Inc.

Sanofi’s Sarclisa Gets EMA Backing In Myeloma, Mirroring FDA OK

The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.

Companies Cancer

Finance Watch: Biotech Stocks Down, But Holding Up Better Than Broader Indices

Public Company Edition: Benefitting from hope that biopharma interventions will help the coronavirus pandemic, the industry is faring better than others in the stock market, including the ability to launch IPOs. Also, BridgeBio leads recent financings and PDL is on track to dissolve by year-end.

Financing Business Strategies

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Drug Review Drug Approval Standards

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Karyopharm Therapeutics Inc.
  • Senior Management
  • Michael Kauffman, MD, PhD, CEO
    Michael Falvey, EVP, CFO
    Sharon Shacham, PhD, Pres. & CSO
    Christopher Primiano, EVP, CBO
    Anand Varadan, EVP, Chief Commercial Officer
  • Contact Info
  • Karyopharm Therapeutics Inc.
    Phone: (617) 658-0600
    85 Wells Ave.
    2nd Fl.
    Newton, MA 02459
    USA
UsernamePublicRestriction

Register